NewLink nails $7.5M round

NewLink Genetics in Ames, Iowa, has grabbed $7.5 million in a Series D financing designed to accelerate the clinical development of its therapeutic cancer products. The financing involved additional funding from prior investors."NewLink has worked hard to become one of the leaders in the expanding field of cancer immunotherapy," said Dr. Charles Link, chairman and CEO. "The proceeds of this financing will allow us to both rapidly move our lead immunotherapy product for pancreatic cancer into pivotal clinical studies and to advance our IDO inhibitor, D-1MT, into multiple Phase II studies." NewLink release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.